We have been exploring the potential of the neuromodulator, adenosine, to reduce excessive dopamine signaling that contributes to the development and persistence of psychostimulant abuse. Dopamine’s ...

The authors conclude that nonsynaptic release of ATP and subsequent activation of adenosine A 1 receptors contributes to suppression of thalamic activity and tremor, alone and during DBS ...

On Medindia find the complete list of Angiotensin Receptor Blockers drugs with their available forms and strength. More information is available on each drug including their price list.

Consider adenosine A 2A receptor antagonists, for example, which are being evaluated as an adjuvant therapy to L-dopa or D 2 receptor agonists for Parkinson's disease, based on the evidence of ...

Oxford, UK-based Exscientia has been working with German biotech Evotec on the adenosine A2a receptor antagonist, which is being tested as a treatment for adult patients with advanced solid tumours.

Exploration of adenosine mechanism revealed adenosine receptors as a potentially useful target of therapy in RA.

Exploration of adenosine mechanism revealed adenosine receptors as a potentially useful target of therapy in RA.

This is likely due to caffeine blocking the receptors of a chemical found in human cells called adenosine. It may also be due ...

a drug in the adenosine A2A receptor antagonist class. The Japanese drugmaker said (PDF) the decision wasn’t taken for clinical reasons, as trials suggested the drug had potential as a ...

a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics ...

a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics ...